Syndax Pharmaceuticals
SNDX
Market cap $1.22B

14.25 USD

-0.16

1.11%

At close Jan 24, 4:00 PM EST

After hours

14.45

+0.20

1.40%

1 day

-1.11%

5 days

8.45%

1 month

9.03%

3 months

-24.96%

6 months

-39.36%

Year to date

1.21%

1 year

-27.70%

5 years

102.41%

10 years

18.65%

About: Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.

Employees: 184

Healthcare Pharmaceutical Preparations

Funds holding %

of 6,831 funds

Analysts bullish %

of 5 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

63% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 24

38% more repeat investments, than reductions

Existing positions increased: 83 | Existing positions reduced: 60

7% more funds holding

Funds holding: 195 [Q2] → 209 (+14) [Q3]

0.31% more ownership

Funds ownership: 104.88% [Q2] → 105.19% (+0.31%) [Q3]

3% less call options, than puts

Call options by funds: $15.1M | Put options by funds: $15.6M

6% less capital invested

Capital invested by funds: $1.83B [Q2] → $1.72B (-$106M) [Q3]

18% less funds holding in top 10

Funds holding in top 10: 11 [Q2] → 9 (-2) [Q3]

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$16

12%

upside

Avg. target

$37

157%

upside

High target

$51

258%

upside

5 analyst ratings

4 positive

80%

1 neutral

20%

0 negative

Scotiabank George Farmer 25% 1-year accuracy 5 / 20 met price target	12%upside $16	Sector Perform Maintained	8 Jan 2025
HC Wainwright & Co. Edward White 28% 1-year accuracy 42 / 148 met price target	258%upside $51	Buy Reiterated	10 Dec 2024
JP Morgan Anupam Rama 24% 1-year accuracy 14 / 59 met price target	167%upside $38	Overweight Maintained	21 Nov 2024
Citigroup Yigal Nochomovitz 27% 1-year accuracy 12 / 45 met price target	216%upside $45	Buy Maintained	19 Nov 2024
Goldman Sachs Chris Shibutani 40% 1-year accuracy 4 / 10 met price target	132%upside $33	Buy Maintained	7 Nov 2024

See Analyst Rankings

Financial journalist opinion

Based on 5 articles about SNDX published over the past 30 days

Neutral

PRNewsWire

1 week ago

Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes

– U.S. launch expected in early February – – Niktimvo is the first and only approved treatment for chronic GVHD that targets CSF-1R to reduce the drivers of inflammation and fibrosis – – Pivotal data from the AGAVE-201 trial supporting FDA approval show treatment with Niktimvo resulted in durable responses across all organs studied and patient subgroups – WILMINGTON, Del. and WALTHAM, Mass.

Neutral

PRNewsWire

1 week ago

Syndax Highlights Recent Accomplishments and Anticipated 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference

– Launched Revuforj® (revumenib) for treatment of R/R acute leukemia with a KMT2A translocation in adult and pediatric patients one year and older – – Revumenib added to NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)for AML and ALL – – Niktimvo™ (axatilimab-csfr) approved by U.S. FDA for treatment of chronic GVHD after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg – – sNDA filing for revumenib in R/R mNPM1 AML expected in 1H25 based on positive pivotal data from AUGMENT-101 trial – WALTHAM, Mass. , Jan. 13, 2025 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX) will present at the 43rd Annual J.P.

Neutral

PRNewsWire

2 weeks ago

Kuehn Law Encourages Investors of Syndax Pharmaceuticals, Inc. to Contact Law Firm

NEW YORK , Jan. 7, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.

Neutral

PRNewsWire

2 weeks ago

Syndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass. , Jan. 7, 2025 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A.

Neutral

PRNewsWire

3 weeks ago

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

WALTHAM, Mass. , Jan. 3, 2025 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on January 1, 2025 the Company granted inducement awards to purchase up to 123,100 shares of common stock to five new employees under the Company's 2023 Inducement Plan.

Neutral

PRNewsWire

1 month ago

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) for Potential Breaches of Fiduciary Duty By Its Board of Directors

NEW YORK , Dec. 19, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX). If you are a shareholder of Syndax Pharmaceuticals, Inc. and are interested in obtaining additional information regarding this investigation, free of charge, please visit us at: https://pjlfirm.com/syndax-pharmaceuticals-inc/ You may also contact Robert H.

Neutral

PRNewsWire

1 month ago

Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial

– Subgroup analyses from Ph 2 protocol-defined R/R mNPM1 AML efficacy population (N=64) show responses across all major subgroups, including heavily pretreated patients – – 26% CR+CRh (20/77) and 48% ORR (37/77) in all enrolled patients who met the efficacy evaluable criteria in Ph 2 R/R mNPM1 AML cohort – – 100% ORR (37/37) and 95% CRc (35/37) in BEAT AML trial exploring revumenib in combination with venetoclax/azacitidine in newly diagnosed mNPM1 or KMT2Ar AML – – BEAT AML data highlight the potential for revumenib to advance the current standard of care – WALTHAM, Mass. , Dec. 9, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced additional positive data from the AUGMENT-101 trial of Revuforj® (revumenib) in relapsed or refractory (R/R) mutant NPM1 (mNPM1) acute myeloid leukemia (AML) and the BEAT AML trial of revumenib in combination with venetoclax and azacitidine in newly diagnosed AML patients.

$Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial$